Core Insights - Sight Sciences, Inc. appointed Gerhard (Gary) F. Burbach to its Board of Directors, effective April 21, 2025, serving as a Class II director until the 2026 Annual Meeting of Stockholders [1] - The appointment is expected to enhance the company's strategic direction in the surgical glaucoma and dry eye segments, which are significant growth areas in eye care [2] Company Overview - Sight Sciences is focused on developing and commercializing innovative interventional technologies aimed at transforming eye care and improving patient outcomes [3] - The company's key products include the OMNI® Surgical System for glaucoma surgery and the TearCare® System for treating evaporative dry eye disease [3] Leadership Background - Gary Burbach has extensive experience in the medtech industry, having previously served as CEO of Thoratec Corporation and held leadership roles in various medical device companies [2] - His expertise in market development and operational leadership is anticipated to be beneficial for Sight Sciences as it seeks to maintain its leadership position in the surgical glaucoma segment and expand market access in the dry eye segment [2]